Iowa 2025-2026 Regular Session Status: Enacted

SF 233 — A bill for an act relating to the right to try Act.

Last action — Signed by Governor.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Senate
  4. ✓
    Passed House
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced February 10, 2025. Enacted.

Signed by Governor Kim Reynolds (Republican) on May 19, 2025.

Prognosis

Likely to advance 70% · moderate confidence

Where this bill stands today.

Odds of enactment

High

How often bills like it became law.

  • Enacted

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

  • Cleared a recorded vote

    Passed 3 recorded votes so far.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Bill Text

What changed in the latest version

265 added · 290 removed

Plain-language change summary

The changes in Senate File 233 clarify the requirements for patients seeking access to experimental treatments. Specifically, patients must now have "exhausted all other United States Food and Drug Administration-approved treatment options" under certain conditions, rather than just "considered" them. This distinction emphasizes that patients need to have actively tried and failed other treatments before accessing investigational options, which could help ensure that these experimental treatments are used more responsibly and effectively.

→
Previous
Latest
STATE OF IOWA KIM REYNOLDS GOVERNOR My1,225 heHnrbleulae ertryfStefIwa tteaiol esMie,Iwa539 earr.erty, Ieeytast:
Senate File 233 - Enrolled Senate File 233 AN ACT RELATING TO THE RIGHT TO TRY ACT.
eaeie23,nAtrligtoergtoryc.
heaoeSnteieshrbyprvednhsde.
ingl, nls ovrorfIwa c:
ertryfheeae lrkfheose STATE CAPITOL DES 539 1.1511PAX575327WWW.GOVERNOR.IOWA.GOV fi ItI I1I ÎiIN•"• i I .•I 1 Iil•"'1 I1 :
.IÎIIIII••'ÎIIIÎIIIIII11iI 111/W •+ • r, 001 ;➢PI1 1 I I IiI1I l1 1 1 11 1 IZ A L .
zX SS 1' ,N 'I1 3 Ih ' C i1 • •N I 9^IûI1I11 III II1?I11 I 1I 1 IEI I]IFI A1 1 1 !1l Senate File 233 AN ACT RELATING TO THE RIGHT TO TRY ACT.
Section 1 .
Section 1.
'Eligible facility"" means an institution operating under a federalwide assurance for the protection of human subjects pursuant to 42 U.S.C.
“Eligible facility” means an institution operating under a federalwide assurance for the protection of human subjects pursuant to 42 U.S.C.
1.
'Eligible patient"" means an individual who meets all of the following conditions specified under paragraph 'a "" or "b" a.
“Eligible patient” means an individual who meets all of the following conditions specified under paragraph “a” or “b”:
(1) Has a terminal illness, attested to by the patient's treating physician.
a.
(1) Has a terminal illness, attested to by the patient’s treating physician.
b.
e- (3) Has received a recommendation from the individual's physician for an investigational drug, biological product, or device.
c.
Senate File 233, p .
(3) Has received a recommendation from the individual’s physician for an investigational drug, biological product, or device.
2 d• ( 4) Has given written informed consent for the use of the investigational drug, biological product, or device.
Senate File 233, p.
e:
2 d.
(5) Has documentation from the individuals physician that the individual meets the requirements of this oub3cction paragraph "a b.
(4) Has given written informed consent for the use of the investigational drug, biological product, or device.
( 1) Has a life-threatening or severely debilitating illness, attested to by the patient's treating physician.
e.
(5) Has documentation from the individual’s physician that the individual meets the requirements of this subsection paragraph “a”.
b.
(1) Has a life-threatening or severely debilitating illness, attested to by the patient’s treating physician.
(3) Has received a recommendation from the individual's physician for an individualized investigational treatment, based on an analysis of the patients genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products such as enzymes and other types of proteins, or metabolites.
(3) Has received a recommendation from the individual’s physician for an individualized investigational treatment, based on an analysis of the patient’s genomic sequence, human chromosomes, deoxyribonucleic acid, ribonucleic acid, genes, gene products such as enzymes and other types of proteins, or metabolites.
(5) Has documentation from the individual's physician that the individual meets the requirements of this paragraph "b -.
(5) Has documentation from the individual’s physician that the individual meets the requirements of this paragraph “b”.
-Individualized investigational treatment - means a drug, biological product, or device that i s unique to, and produced exclusively for use by, an individual patient, based on the individual patient's own genetic profile, and is provided in a manner that is consistent with a federalwide assurance for the protection of human subjects.
“Individualized investigational treatment” means a drug, biological product, or device that is unique to, and produced exclusively for use by, an individual patient, based on the individual patient’s own genetic profile, and is provided in a manner that is consistent with a federalwide assurance for the protection of human subjects.
Individualized investigational treatment" includes but is not limited to individualized gene therapy, antisense oligonucleotides, and individualized neoantigen vaccines.
“Individualized investigational treatment” includes but is not limited to individualized gene therapy, antisense oligonucleotides, and individualized neoantigen vaccines.
2.
investigational drug, biological product, or device -means a drug, biological product, or device that has successfully completed phase 1 of a United States food and drug administration-approved clinical trial but has not yet been approved for general use by the United States food and drug administration and remains under investigation in a United States food and drug administration-approved clinical trial.
“Investigational drug, biological product, or device” means a drug, biological product, or device that has successfully completed phase 1 of a United States food and drug administration-approved clinical trial but has not yet been approved for general use by the United States food and drug administration and remains under investigation in a United States food and drug administration-approved clinical trial.
-Terminal illness- means a progressive disease or medical or surgical condition that entails significant Senate File 233, p .
5.
“Terminal illness” means a progressive disease or medical or surgical condition that entails significant Senate File 233, p.
•- 6.
4.
"Written informed consent" means a written document that is signed by the patient, a parent of a minor patient, or a legal guardian or other legal representative of the patient and attested to by the patient's treating physician and a witness and that includes, at a minimum, all of the following:
6.
“Written informed consent” means a written document that is signed by the patient, a parent of a minor patient, or a legal guardian or other legal representative of the patient and attested to by the patient’s treating physician and a witness and that includes, at a minimum, all of the following:
If the patient is an eligible patient as specified in subsection 2, paragraph -a-:
If the patient is an eligible patient as specified in subsection 2, paragraph “a”:
b,- () An attestation that the patient concurs with the patients treating physician in believing that all products and treatments approved by the United States food and drug administration are unlikely to prolong the patient's life.
b.
e:
(2) An attestation that the patient concurs with the patient’s treating physician in believing that all products and treatments approved by the United States food and drug administration are unlikely to prolong the patient’s life.
() Clear identification of the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
c.
() A description of the best and worst potential outcomes of using the investigational drug, biological product, or device and a realistic description of the most likely outcome.
(3) Clear identification of the specific proposed investigational drug, biological product, or device that the patient is seeking to use.
d.
Show all 70 changed rows (30 more)
Previous
Latest
(4) A description of the best and worst potential outcomes of using the investigational drug, biological product, or device and a realistic description of the most likely outcome.
The description shall be based on the treating physician's knowledge of the proposed investigational drug, biological product, or device in conjunction with an awareness of the patient's condition.
The description shall be based on the treating physician’s knowledge of the proposed investigational drug, biological product, or device in conjunction with an awareness of the patient’s condition.
() A statement that the patient's health plan or third-party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the investigational drug, biological product, or device, unless they are specifically required to do so by law or contract.
e.
() A statement that the patient's eligibility for Senate File 233, p.
(5) A statement that the patient’s health plan or third-party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the investigational drug, biological product, or device, unless they are specifically required to do so by law or contract.
f.
(6) A statement that the patient’s eligibility for Senate File 233, p.
g—, (7) A statement that the patient understands that the patient is liable for all expenses consequent to the use of the investigational drug, biological product, or device and that this liability extends to the patient's estate unless a contract between the patient and the manufacturer of the investigational drug, biological product, or device states otherwise.
g.
(7) A statement that the patient understands that the patient is liable for all expenses consequent to the use of the investigational drug, biological product, or device and that this liability extends to the patient’s estate unless a contract between the patient and the manufacturer of the investigational drug, biological product, or device states otherwise.
If the patient is an eligible patient as specified in subsection 2, paragraph "b -:
If the patient is an eligible patient as specified in subsection 2, paragraph “b”:
(2) An attestation that the patient concurs with the patients treating physician in believing that all currently approved and conventionally recognized products and treatments are unlikely to prolong the patient's life.
(2) An attestation that the patient concurs with the patient’s treating physician in believing that all currently approved and conventionally recognized products and treatments are unlikely to prolong the patient’s life.
The description shall be based on the treating physician's knowledge of the proposed individualized investigational treatment in conjunction with an awareness of the patient's condition.
The description shall be based on the treating physician’s knowledge of the proposed individualized investigational treatment in conjunction with an awareness of the patient’s condition.
() A statement that the patient's health plan or third-party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the individualized investigational treatment, unless they are specifically required to do so by law or contract.
(5) A statement that the patient’s health plan or third-party administrator and provider are not obligated to pay for any care or treatments consequent to the use of the individualized investigational treatment, unless they are specifically required to do so by law or contract.
Senate File 233, p .
Senate File 233, p.
5 (6) A statement that the patient's eligibility for hospice care may be withdrawn if the patient begins curative treatment with the individualized investigational treatment and that hospice care may be reinstated if this treatment ends and the patient meets hospice eligibility requirements.
5 (6) A statement that the patient’s eligibility for hospice care may be withdrawn if the patient begins curative treatment with the individualized investigational treatment and that hospice care may be reinstated if this treatment ends and the patient meets hospice eligibility requirements.
(7) A statement that the patient understands that the patient is liable for all expenses consequent to the use of the individualized investigational treatment and that this liability extends to the patient's estate, unless a contract between the patient and the manufacturer of the individualized investigational treatment states otherwise.
(7) A statement that the patient understands that the patient is liable for all expenses consequent to the use of the individualized investigational treatment and that this liability extends to the patient’s estate, unless a contract between the patient and the manufacturer of the individualized investigational treatment states otherwise.
A manufacturer of an investigational drug, biological product, or device or a manufacturer operating within, and in compliance with all requirements applicable to, an eligible facility may make available, and an eligible patient, as applicable under section 144E.1, subsection 2 , paragraph 'à"' or 'b , may request from a manufacturer of an investigational drug, biological product, or device, or a manufacturer operating within, and in compliance with all requirements applicable to, an eligible facility, the manufacturer's investigational drug, biological product, or device, or the manufacturer's individualized investigational treatment under this chapter.
A manufacturer of an investigational drug, biological product, or device or a manufacturer operating within, and in compliance with all requirements applicable to, an eligible facility may make available, and an eligible patient, as applicable under section 144E.1, subsection 2, paragraph “a” or “b”, may request from a manufacturer of an investigational drug, biological product, or device, or a manufacturer operating within, and in compliance with all requirements applicable to, an eligible facility, the manufacturer’s investigational drug, biological product, or device, or the manufacturer’s individualized investigational treatment under this chapter.
A An eligible facility, or a manufacturer described in subsection 1 , that is in compliance with all applicable requirements, may do any of the following:
A An eligible facility, or a manufacturer described in subsection 1, that is in compliance with all applicable requirements, may do any of the following:
Provide an investigational drug, biological product, or device, or an individualized investigational treatment to an eligible patient, as applicable under section 144E.1, subsection 2 , paragraph "a"' or'b -, without receiving compensation.
Provide an investigational drug, biological product, or device, or an individualized investigational treatment to an eligible patient, as applicable under section 144E.1, subsection 2, paragraph “a” or “b”, without receiving compensation.
Require an eligible patient, as applicable under section 144E.1, subsection 2 , paragraph -a- or ­b -, to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device, or the individualized investigational treatment.
Require an eligible patient, as applicable under section 144E.1, subsection 2, paragraph “a” or “b”, to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device, or the individualized investigational treatment.
This chapter does not expand the coverage required of an insurer under Title XIII, subtitle 1 .
This chapter does not expand the coverage required of an insurer under Title XIII, subtitle 1.
A health plan, third-party administrator, or governmental agency may, but is not required to, provide coverage for the cost of an investigational drug, biological product, or device, e• the cost of an individualized investigational treatment, the cost of services related to the use of an investigational drug, biological product, or device, or the cost of services related to the use of an individualized investigational treatment under this chapter.
A health plan, third-party administrator, or governmental agency may, but is not required to, provide coverage for the cost of an investigational drug, biological product, or device, or the cost of an individualized investigational treatment, the cost of services related to the use of an investigational drug, biological product, or device, or the cost of services related to the use of an individualized investigational treatment under this chapter.
This chapter does not require any governmental agency to pay costs associated with the use, care, or treatment of a patient with an investigational drug, biological product, or device, or an individualized investigational treatment.
This chapter does not require any governmental agency to pay costs associated with the use, care, or treatment of a patient with an investigational drug, biological product, or device, or an individualized investigational treatment .
If a patient dies while being treated $-r with an investigational drug, biological product, or device, or an individualized investigational treatment, the patient's heirs are not liable for any outstanding debt related to the treatment or lack of insurance due to the treatment, unlC3s othcrwisc rcquircd by law.
If a patient dies while being treated by with an investigational drug, biological product, or device, or an individualized investigational treatment, the patient’s heirs are not liable for any outstanding debt related to the treatment or lack of insurance due to the treatment, unless otherwise required by law.
7 medicine created under chapter 147 shall not revoke, fail to renew, suspend, or take any action against a physician's license based solely on the physician's recommendations to an eligible patient regarding access to or treatment with an investigational drug, biological product, or device, or an individualized investigational treatment.
7 medicine created under chapter 147 shall not revoke, fail to renew, suspend, or take any action against a physician’s license based solely on the physician’s recommendations to an eligible patient regarding access to or treatment with an investigational drug, biological product, or device, or an individualized investigational treatment .
To the extent consistent with federal law, an entity responsible for Medicare certification shall not take action against a physician's Medicare certification based solely on the physician's recommendation that a patient have access to an investigational drug, biological product, or device, or an individualized investigational treatment.
To the extent consistent with federal law, an entity responsible for Medicare certification shall not take action against a physician’s Medicare certification based solely on the physician’s recommendation that a patient have access to an investigational drug, biological product, or device, or an individualized investigational treatment.
An official, employee, or agent of this state shall not block or attempt to block an eligible patient's access to an investigational drug, biological product, or device, or to an individualized investigational treatment.
An official, employee, or agent of this state shall not block or attempt to block an eligible patient’s access to an investigational drug, biological product, or device, or to an individualized investigational treatment .
1_ 2, •••• AMY SINCY ,R PAT GRASSLE President of the Senate Speaker of the House I hereby certify that this bill originated in the Senate and is known as Senate File 233, Ninety-first General Assembly.
______________________________ ______________________________ AMY SINCLAIR PAT GRASSLEY President of the Senate Speaker of the House I hereby certify that this bill originated in the Senate and is known as Senate File 233, Ninety-first General Assembly.
W.
______________________________ W.
CHARLES SMITHSON Secre ;ry he Senate Approved 2025 KI' R:
CHARLES SMITHSON Secretary of the Senate Approved _______________, 2025 ______________________________ KIM REYNOLDS Governor
NOLDS Governor
⬇ Download PDF
View plain text versions (4)

Amendments

2 amendments

Click Show changes on an amendment above to see how it modifies the bill.

Action History

  1. Signed by Governor.

  2. Reported correctly enrolled, signed by President and Speaker, and sent to Governor.

  3. Message from Senate.

  4. Immediate message.

  5. Passed Senate, yeas 46, nays 0.

  6. Senate concurred with S-3038.

  7. Explanations of votes.

  8. Explanation of vote.

  9. Message from House, with amendment S-3038.

  10. Immediate message.

  11. Passed House, yeas 89, nays 0.

  12. Amendment H-1132 adopted.

  13. Substituted for HF 802.

  14. Amendment H-1132 filed.

  15. Placed on calendar under unfinished business.

  16. Read first time, passed on file.

  17. Message from Senate.

  18. Immediate message.

  19. Passed Senate, yeas 48, nays 0.

  20. Committee report, approving bill.

  21. Introduced, placed on calendar.

Sponsors

  • COMMITTEE ON HEALTH AND HUMAN SERVICES · Primary

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 149 not signed on

Sponsors (1)

  • COMMITTEE ON HEALTH AND HUMAN SERVICES

Co-sponsors (0)

None.

Not signed on (149)

149 members have not signed on to this bill.

Show all 149 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

Shall the bill pass?

Passed 46 Yea · 0 Nay · 4 Other
Party YeaNayPresentNot Voting
Republican 31001
Democrat 14002
Unaffiliated 1001
Total 46004
% of votes cast 92%0%0%8%
How each member voted (50)
Member Party Vote
Celsi — Not Voting
De Witt — Yea
Art Staed Democrat Yea
Cindy Winckler Democrat Yea
Herman C. Quirmbach Democrat Yea
Izaah Knox Democrat Yea
Janet Petersen Democrat Not Voting
Janice Weiner Democrat Yea
Liz Bennett Democrat Not Voting
Matt Blake Democrat Yea
Mike Zimmer Democrat Yea
Molly Donahue Democrat Yea
Sarah Trone Garriott Democrat Yea
Sarah Trone Garriott Democrat Yea
Thomas Townsend Democrat Yea
Tony Bisignano Democrat Yea
William A. Dotzler Jr. Democrat Yea
Zach Wahls Democrat Yea
Adrian Dickey Republican Yea
Amy Sinclair Republican Yea
Annette Sweeney Republican Yea
Carrie Koelker Republican Yea
Charlie McClintock Republican Yea
Cherielynn Westrich Republican Yea
Dan Zumbach Republican Not Voting
Dave Sires Republican Yea
David D. Rowley Republican Yea
Dawn Driscoll Republican Yea
Dennis Guth Republican Yea
Doug Campbell Republican Yea
Jack Whitver Republican Yea
Jason Schultz Republican Yea
Jeff Reichman Republican Yea
Jeff Taylor Republican Yea
Jesse Green Republican Yea
Julian B. Garrett Republican Yea
Kara Warme Republican Yea
Ken Rozenboom Republican Yea
Kerry Gruenhagen Republican Yea
Kevin Alons Republican Yea
Lynn Evans Republican Yea
Mark Costello Republican Yea
Mark S. Lofgren Republican Yea
Mike Bousselot Republican Yea
Mike Klimesh Republican Yea
Mike Pike Republican Yea
Sandy Salmon Republican Yea
Scott Webster Republican Yea
Tim Kraayenbrink Republican Yea
Tom Shipley Republican Yea

Official roll call →

Shall the bill pass?

Passed 89 Yea · 0 Nay · 11 Other
Party YeaNayPresentNot Voting
Democrat 28004
Unaffiliated 4001
Republican 59006
Total 910011
% of votes cast 89%0%0%11%
How each member voted (102)
Member Party Vote
Jr. — Yea
Kniff — Yea
Scheetz — Yea
Sexton — Yea
Open — Not Voting
Adam Zabner Democrat Yea
Aime Wichtendahl Democrat Yea
Amy Nielsen Democrat Yea
Austin Baeth Democrat Yea
Beth Wessel-Kroeschell Democrat Yea
Bob Kressig Democrat Yea
Brian Meyer Democrat Yea
Daniel Gosa Democrat Yea
David Jacoby Democrat Not Voting
Dr. Megan L. Srinivas Democrat Yea
Elinor A. Levin Democrat Yea
Elizabeth Wilson Democrat Yea
Eric J. Gjerde Democrat Yea
Heather Matson Democrat Yea
J.D. Scholten Democrat Yea
Jeff Cooling Democrat Yea
Jennifer Konfrst Democrat Yea
Jerome Amos Jr. Democrat Yea
Josh Turek Democrat Yea
Ken Croken Democrat Yea
Kenan Judge Democrat Not Voting
Larry McBurney Democrat Yea
Lindsay James Democrat Yea
Mary Lee Madison Democrat Not Voting
Monica Kurth Democrat Yea
Rick L. Olson Democrat Yea
Rob Johnson Democrat Not Voting
Ross Wilburn Democrat Yea
Ruth Ann Gaines Democrat Yea
Sean Bagniewski Democrat Yea
Timi M. Brown-Powers Democrat Yea
Tracy A. Ehlert Democrat Yea
Ann Meyer Republican Yea
Austin Harris Republican Yea
Barb Kniff McCulla Republican Yea
Bill Gustoff Republican Not Voting
Bob Henderson Republican Yea
Bobby Kaufmann Republican Yea
Brent Siegrist Republican Not Voting
Brett Barker Republican Yea
Brian K. Lohse Republican Yea
Brooke Boden Republican Yea
Carter F. Nordman Republican Yea
Chad Behn Republican Yea
Chad Ingels Republican Yea
Charley Thomson Republican Yea
Christian A. Hermanson Republican Yea
Cindy Golding Republican Yea
Craig P. Johnson Republican Yea
Craig Steven Williams Republican Yea
Dan Gehlbach Republican Yea
David E. Young Republican Yea
David L. Blom Republican Yea
David Sieck Republican Not Voting
Dean Fisher Republican Yea
Derek Wulf Republican Yea
Devon Wood Republican Yea
Dr. Steven P. Bradley Republican Yea
Eddie Andrews Republican Yea
Gary M. Mohr Republican Yea
Hans C. Wilz Republican Not Voting
Heather Hora Republican Yea
Helena Hayes Republican Yea
Henry Stone Republican Yea
Jacob Bossman Republican Yea
Jane Bloomingdale Republican Yea
Jason Gearhart Republican Yea
Jennifer J. Smith Republican Yea
John H. Wills Republican Yea
Jon Dunwell Republican Yea
Joshua Meggers Republican Yea
Judd Lawler Republican Yea
Mark Cisneros Republican Yea
Mark I. Thompson Republican Yea
Matt W. Windschitl Republican Yea
Matthew Rinker Republican Not Voting
Megan Jones Republican Yea
Michael R. Bergan Republican Yea
Mike Vondran Republican Yea
Norlin G. Mommsen Republican Yea
Pat Grassley Republican Yea
Ray Sorensen Republican Yea
Ryan Weldon Republican Yea
Sam Wengryn Republican Yea
Samantha Fett Republican Yea
Shannon Latham Republican Not Voting
Shannon Lundgren Republican Yea
Skyler Wheeler Republican Yea
Steven C. Holt Republican Yea
Taylor R. Collins Republican Yea
Thomas Gerhold Republican Yea
Thomas Jay Moore Republican Yea
Thomas M. Jeneary Republican Yea
Tom Determann Republican Yea
Tom Shipley Republican Yea
Travis M. Sitzmann Republican Yea
Zach Dieken Republican Yea

Official roll call →

Shall the bill pass?

Passed 48 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Republican 33000
Democrat 15001
Unaffiliated 1001
Total 49002
% of votes cast 96%0%0%4%
How each member voted (51)
Member Party Vote
Celsi — Not Voting
De Witt — Yea
Art Staed Democrat Yea
Cindy Winckler Democrat Yea
Herman C. Quirmbach Democrat Yea
Izaah Knox Democrat Yea
Janet Petersen Democrat Not Voting
Janice Weiner Democrat Yea
Liz Bennett Democrat Yea
Matt Blake Democrat Yea
Mike Zimmer Democrat Yea
Molly Donahue Democrat Yea
Sarah Trone Garriott Democrat Yea
Sarah Trone Garriott Democrat Yea
Thomas Townsend Democrat Yea
Tony Bisignano Democrat Yea
William A. Dotzler Jr. Democrat Yea
Zach Wahls Democrat Yea
Adrian Dickey Republican Yea
Amy Sinclair Republican Yea
Annette Sweeney Republican Yea
Carrie Koelker Republican Yea
Charlie McClintock Republican Yea
Cherielynn Westrich Republican Yea
Dan Dawson Republican Yea
Dan Zumbach Republican Yea
Dave Sires Republican Yea
David D. Rowley Republican Yea
Dawn Driscoll Republican Yea
Dennis Guth Republican Yea
Doug Campbell Republican Yea
Jack Whitver Republican Yea
Jason Schultz Republican Yea
Jeff Reichman Republican Yea
Jeff Taylor Republican Yea
Jesse Green Republican Yea
Julian B. Garrett Republican Yea
Kara Warme Republican Yea
Ken Rozenboom Republican Yea
Kerry Gruenhagen Republican Yea
Kevin Alons Republican Yea
Lynn Evans Republican Yea
Mark Costello Republican Yea
Mark S. Lofgren Republican Yea
Mike Bousselot Republican Yea
Mike Klimesh Republican Yea
Mike Pike Republican Yea
Sandy Salmon Republican Yea
Scott Webster Republican Yea
Tim Kraayenbrink Republican Yea
Tom Shipley Republican Yea

Official roll call →

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors SF 233?
SF 233 is sponsored by COMMITTEE ON HEALTH AND HUMAN SERVICES.
What is the current status of SF 233?
This bill has been enacted into law. Introduced February 10, 2025. Enacted.
Where can I track SF 233?
Track SF 233 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SF 233

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SF 233

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →